ABOUT US
WHO WE ARE
THE TEAM
Joana Simões Correia
Renato Cardoso
Luisa Marques
Silvia Rodrigues
Cláudia Gomes
Ricardo Neves
Board and Advisors
FINOVA
News
Exogenus Therapeutics on the Top 500 deeptech startups shortlist of Hello Tommorrow
Exogenus is amongst the 500 deeptech startups running for the Hello Tomorrow Global Challenge. The Hello Tomorrow Global Challenge is a worldwide renowned science & technology startup competition designed specifically to address the needs of deeptech entrepreneurs across several different industries and technologies. Finalists will be announced in January 2019 and the Global Summit will take place in[…]
Estamos a recrutar um Estagiário(a) Adminstrativo(a)
Exogenus Therapeutics é uma start-up de base tecnológica dedicada ao desenvolvimento de terapias inovadoras. Com uma equipa jovem e dinâmica localizada no parque biotecnológico de Cantanhede (Biocant Park), pretende recrutar um estagiário para estágio IEFP para apoiar a atividade administrativa e financeira fazendo a ponte entre a Direção e os serviços de Contabilidade, com[…]
Graça Raposo joins Exogenus Therapeutics Advisory Board
We are glad to announce that Graça Raposo, one of the first scientists worldwide who recognized the biological role of Extracellular Vesicles (EVs) in human biology, has joined our Advisory Board. Commonly referred within experts as “the mother of exosomes”, Graça Raposo has been extensively recognized in the field, and received many distinctions such as the CNRS[…]
Exogenus presents poster at ISEV 2018 Annual meeting
Exogenus is presenting a poster at ISEV 2018 Annual meeting taking place in Barcelona between 2-6 May. With over 1,000 attendees, ISEV2018 gathers experts and researchers on extracellular vesicle research, covering the latest progresses in exosomes, microvesicles. Exogenus is one of the few companies worldwide developing EV-based therapeutics. Silvia Rodrigues is presenting a poster on “Development[…]
Technology licensed by Exogenus presented at 14th Portuguese Congress of Diabetes
Exogenus is developing promising therapeutics for the treatment of chronic and acute wounds, among which are diabetic foot ulcers, some of the most debilitating and hard-to-heal. The lead technology licensed and under development by Exogenus for the treatment of wounds, is owned by Crioestaminal and Biocant, and relates to the use of exosomes secreted by[…]
Exogenus present at 1st Meeting on Vesicular Biology
Silvia Rodrigues, PhD student at Exogenus Therapeutics, presented a poster with results on research and development work done on the automatization of cord blood processing for production of an exosome-based medicinal product and its relevance for the scaling up of clinical-grade manufacturing process. Held in Coimbra in February 2018, the 1st Meeting on Vesicular Biology of[…]
Exogenus recognized at BioEurope 2017
Exogenus was recognized at BioEurope 2017, one of the biggest biotech industry events! Listen to Joana Simões Correia on Exogenus Therapeutics: Event organizers, EBD Group and Johnson & Johnson Innovation, recognized how hard a task it was to choose the winner at this edition. https://labiotech.eu/startup-slam-bio-europe-2017-winner/
Exogenus Therapeutics – one of the hottest startups of 2017!
Exogenus was one of the 20 biotech startups selected to participate at Bio Europe 2017 Startup Slam taking place on November 7th in Berlin. Participants will have the chance to present in front of a jury of investors, dealmakers and biotech KOL’s. Check out Labiotech’s article on the event. Joana Correia said: “Bio Europe Startup Slam is[…]
Exogenus distinguished at Merck Venture Lounge
Exogenus was distinguished as one of the most innovative Life Sciences & Medtech projects in Europe at Merck Venture Lounge, 2017! The Venture Lounge is an initiative of EASME through SME Instrument Phase 3 services. https://ec.europa.eu/easme/en/news/pitching-contest-merck-venture-lounge-and-sme-instrument-starts-today Joana Correia on this award: “For a startup it’s really important to have the recognition of relevant industry players, special on[…]
Exogenus Therapeutics featured in article on Exosome Technology
Exosome Companies – Tiny Exosomes, Enormous Potential “Recently, exosomes have been gaining momentum as a novel strategy for accessing the therapeutic effects of stem cells without the risks and difficulties of administering the cells to patients. Exosome companies are multiplying in number, with new market entrants popping up rapidly.” in BioInformant